Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REM0045392 in healthy volunteers
NCT07016464Phase 1Terminated
- Sponsor
- reMYND
- Start
- Mar 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of REM0045392 in Alzheimer's disease (AD) (14 arms), sponsored by reMYND. Primary endpoint: Treatment-Related Adverse Events. Started Mar 2025; status: terminated.
02
Drugs
REM0045392
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07016464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07016464.